Global Hypercholesterolemia Drugs Market 2016-2020

About Hypercholesterolemia

Hypercholesterolemia is characterized by high levels of total cholesterol and LDL-C in the blood. High cholesterol levels can cause CVDs such as stroke and atherosclerosis. The typical range of total blood cholesterol is 140-200 mg/dL.Blood cholesterol contains individual components such as LDL-C and HDL-C. LDL carries cholesterol to the body and HDL removes cholesterol from the cells by reversing cholesterol transport to the liver.

Technavio’s analysts forecast the global hypercholesterolemia drugs market to decline at a CAGR of 6.78% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global hypercholesterolemia drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generics, and off-label drugs used to treat hypercholesterolemia.The market is divided into the following segments based on geography:

• Americas
• APAC
• EMEA

Technavio's report, Global Hypercholesterolemia Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

• AbbVie
• Aegerion Pharmaceuticals
• AstraZeneca
• Merck
• Pfizer
• Sanofi

Other prominent vendors

• Alnylam Pharmaceuticals
• Amarin
• Amgen
• AtheroNova
• Aurobindo Pharma
• Biocon
• Biospherics
• Bristol-Myers Squibb
• Catabasis Pharmaceuticals
• Cerenis Therapeutics
• Cipla
• CJ HealthCare
• CKD Bio
• Concord Biotech
• CymaBay Therapeutics
• Daewoong Pharmaceutical
• Daiichi Sankyo
• Eli Lilly
• Esperion Therapeutics
• GlaxoSmithKline
• HanAll BioPharma
• JW Pharmaceuticals
• Kadmon Pharmaceuticals
• Kowa Company
• Laboratoires
• Livzon Pharmaceutical
• Lupin Pharmaceuticals
• Madrigal Pharmaceuticals
• Merz Pharmaceuticals
• Mylan
• Novartis
• Regeneron Pharmaceuticals
• ReGenX Biosciences
• Santaris Pharma
• Serometrix
• Sun Pharmaceutical
• Arbutus Biopharma
• Teva Pharmaceuticals
• Torrent Pharmaceuticals
• Zydus Cadila

Market driver

• Rising prevalence of chronic diseases
• For a full, detailed list, view our report

Market challenge

• Loss of patent exclusivity of branded therapies
• For a full, detailed list, view our report

Market trend

• Expected entry of cost-effective OTC versions
• For a full, detailed list, view our report

Key questions answered in this report

• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Press Release

Technavio Announces the Publication of its Research Report – Global Hypercholesterolemia Drugs Market 2016-2020

Technavio recognizes the following companies as the key players in the global hypercholesterolemia drugs market: AbbVie, Aegerion Pharmaceuticals, AstraZeneca, Merck, Pfizer, and Sanofi.

Other Prominent Vendors in the market are: Alnylam Pharmaceuticals, Amarin, Amgen, AtheroNova, Aurobindo Pharma, Biocon, Biospherics, Bristol-Myers Squibb, Catabasis Pharmaceuticals, Cerenis Therapeutics, Cipla, CJ HealthCare, CKD Bio, Concord Biotech, CymaBay Therapeutics, Daewoong Pharmaceutical, Daiichi Sankyo, Eli Lilly, Esperion Therapeutics, GlaxoSmithKline, HanAll BioPharma, JW Pharmaceuticals, Kadmon Pharmaceuticals, Kowa Company, Laboratoires, Livzon Pharmaceutical, Lupin Pharmaceuticals, Madrigal Pharmaceuticals, Merz Pharmaceuticals, Mylan, Novartis, Regeneron Pharmaceuticals, ReGenX Biosciences, Santaris Pharma, Serometrix, Sun Pharmaceutical, Arbutus Biopharma, Teva Pharmaceuticals, Torrent Pharmaceuticals, and Zydus Cadila.

Commenting on the report, an analyst from Technavio’s team said: “One of the major trends for market growth will be the increased use of combination therapies. Combinations of drugs are often used to treat conditions and they are mostly useful in managing lipid abnormalities. Combination therapies have advantages over monotherapies in terms of efficacy and a reduced incidence of adverse effects. Further, combination therapies have lesser manufacturing costs compared to the costs of manufacturing monotherapies administered concurrently, simpler logistics of distribution, and improved patient compliance by reducing the pill burden. Combination therapy in fixed dose combinations containing a statin and another lipid-lowering drug is available in the market.”

According to the report, one of the key drivers for market growth will be rising prevalence of chronic diseases. Chronic conditions such as obesity and diabetes are linked to lipid abnormalities and are a result of health risk behaviors. For instance, the prevalence of obesity has doubled between 1980 and 2014. In 2014, over 1.9 billion individuals were found to be overweight. Of these, over 600 million were obese. In the same year, the global prevalence of diabetes in individuals over 18 years of age was estimated to be 9%. According to a WHO report published in 2014, the global prevalence of diabetes was 8% in 2011 and is expected to rise to 10% by 2030. Regular use of anti-hypercholesterolemia drugs is necessary to lower cholesterol levels and reduce the risk of CVDs.

Further, the report states that stringent regulatory guidelines will be one of the major challenges for the market. The drug approval process across the globe is a stringent process demanding evidence from clinical trial studies. The regulatory authorities carefully study and evaluate the drug related data before approving it for use. The regulatory bodies examine some major factors such as safety, efficacy, carcinogenicity, mitogenicity, pharmacological data, pharmacodynamics effects, and drug interactions. Thus, a drug failing in any of these criteria is likely to receive a complete response letter (CRL) or be rejected by the regulatory agencies. On receiving a CRL, the drug applicant is required to furnish additional data pertaining to the drug. This, in turn, might require additional clinical trials and might increase the R&D expenditure for the drug.

Companies Mentioned

AbbVie, Aegerion Pharmaceuticals, AstraZeneca, Merck, Pfizer, Sanofi, Alnylam Pharmaceuticals, Amarin, Amgen, AtheroNova, Aurobindo Pharma, Biocon, Biospherics, Bristol-Myers Squibb, Catabasis Pharmaceuticals, Cerenis Therapeutics, Cipla, CJ HealthCare, CKD Bio, Concord Biotech, CymaBay Therapeutics, Daewoong Pharmaceutical, Daiichi Sankyo, Eli Lilly, Esperion Therapeutics, GlaxoSmithKline, HanAll BioPharma, JW Pharmaceuticals, Kadmon Pharmaceuticals, Kowa Company, Laboratoires, Livzon Pharmaceutical, Lupin Pharmaceuticals, Madrigal Pharmaceuticals, Merz Pharmaceuticals, Mylan, Novartis, Regeneron Pharmaceuticals, ReGenX Biosciences, Santaris Pharma, Serometrix, Sun Pharmaceutical, Arbutus Biopharma, Teva Pharmaceuticals, Torrent Pharmaceuticals, Zydus Cadila.